Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-35,000
Closed -$49.8K 361
2025
Q2
$49.8K Sell
35,000
-20,000
-36% -$1.27M ﹤0.01% 327
2025
Q1
$70.8K Buy
55,000
+35,000
+175% +$2.44M ﹤0.01% 273
2024
Q4
$19.5K Buy
+20,000
New +$1.43M ﹤0.01% 382
2024
Q2
Sell
-40,000
Closed -$5K 587
2024
Q1
$5K Buy
+40,000
New +$2.4M ﹤0.01% 501
2023
Q4
Sell
-70,000
Closed -$47.3K 556
2023
Q3
$47.3K Buy
+70,000
New +$4.41M ﹤0.01% 492

Other funds holding INCY

UBS O'Connor's INCY Position: Q3 2025 in Review

UBS O'Connor sold out of Incyte (INCY) in Q3 2025, closing a stake of 28,924 shares — an estimated $1.97M sold.

UBS O'Connor first reported a position in INCY in Q2 2013 and held it in 14 quarters. The position peaked at $16.8M in Q3 2017. 713 funds tracked by Wall St. Rank hold INCY as of Q3 2025.

  • UBS O'Connor reported no remaining Incyte position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 28,924 Incyte shares in Q3 2025, an estimated $1.97M.
  • UBS O'Connor first reported a position in Incyte in Q2 2013 and held it in 14 quarters.
  • UBS O'Connor's Incyte position peaked at $16.8M in Q3 2017.
  • 713 funds tracked by Wall St. Rank held Incyte as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.